EL7.AI
StocksMedium•16 November 2026•
4 min read

EMA Committee Recommends RASONQUE After 60% Reduction in Pancreatic Cancer Death Risk

Key Facts

1EMA’s committee recommends authorising RASONQUE for adults after at least one prior systemic treatment.
2The FDA approved the drug on 26 August 2026 for specific indications in metastatic pancreatic cancer.
3RVMD shares closed at $172.29 on 13 November 2026.
4The company is conducting four additional Phase 3 studies of the drug.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended authorising RASONQUE, known scientifically as daraxonrasib, to treat adults with metastatic pancreatic cancer, according to the agency’s page published on 15 October 2026. The recommendation concerns use of the drug as monotherapy for patients who have received at least one prior systemic treatment. A final decision by the European Commission on 16 November, the date around which the report is framed, could not be confirmed. The confirmed European step therefore remains a regulatory recommendation, not final Commission authorisation. The U.S. Food and Drug Administration approved the drug on 26 August 2026 to treat adults meeting specific treatment criteria.

The study results showed a 60% reduction in the risk of death among the group that received daraxonrasib compared with chemotherapy, as reported in coverage of the European recommendation. This finding provides a clinical basis for the recommendation, but does not in itself turn it into a final authorisation decision. The indication cited by the agency also specifies patients who have received at least one prior systemic treatment, and the page reviewed does not extend it to patients regardless of RAS mutation status.

The European recommendation follows U.S. approval recorded by the Food and Drug Administration on 26 August 2026. The U.S. indication covers adults with metastatic pancreatic adenocarcinoma after at least one prior systemic treatment, or patients who are not candidates for multi-agent systemic treatment. The differing wording of the two indications underscores the need to read each decision within its regulatory terms, as the U.S. action does not automatically establish the scope of use in Europe. The U.S. commercial launch date could not be verified in the open sources cited here.

The drug’s assessment included a rolling review, which Spain’s Agency for Medicines and Medical Devices said reduced the evaluation period to less than 150 days, from more than a year. This sets a timeline for the review of the application, while the European recommendation and final decision remain separate regulatory stages. Pricing and reimbursement decisions for the treatment remain tied to each member state, according to the regulatory context accompanying the recommendation. The committee’s recommendation alone therefore does not mean the drug is available or covered uniformly across European markets.

These developments come amid a growing burden of pancreatic cancer in the European Union before Britain’s departure. A study published in 2021 estimated new cases at 109,000 in 2019, compared with 59,000 in 1990, and projected they would rise to 147,000 in 2039. These figures concern the European Union before Britain’s departure, while the 2039 figure is a future projection, not a current annual estimate. This background underscores the public health importance of efforts to develop treatment options for patients with metastatic disease.

In trading, Revolution Medicines shares, listed under the ticker RVMD, closed at $172.29 on 13 November 2026, according to EL7 data. The stock had closed at $200.15 on 9 November, then fell to $193.06 on 10 November, $180.70 on 11 November and $176.35 on 12 November. These closing prices show the share’s course in sessions before the date of the report, but do not establish that its movement was linked to the European recommendation. The available data do not include a closing price for 16 November or a direct market response to a final European decision.

On subsequent development, Revolution Medicines said in a filing with the U.S. Securities and Exchange Commission dated 4 November 2026 that it was advancing four additional global Phase 3 studies of the drug. The studies include first-line treatment settings for metastatic disease and adjuvant treatment, the company said. This points to a broader research programme examining the drug’s use at different stages of treatment. The filing cited here did not specify any future results or regulatory decisions from these studies.

Open on chart